TECHNOLOGY OVERVIEW

The researchers developed the first total synthesis of PDX in 2019. Further optimization led to a more efficient synthesis route that allows to obtain PDX on a gram scale at a fraction of the cost of the biosynthesis method. This creates the opportunity to accelerate pre-clinical and clinical studies in a variety of indications.

Even more impressive, this new synthetic pathway allows the synthesis of small analogues of PDX (and eventually other SPMs) with potent biological actions through a simplified and flexible synthetic route.

Currently, PDX and SPM analogues can be produced at laboratory gram scale quantities (non-GMP).

 

COMPETITIVE ADVANTAGES

• Low-cost synthesis of PDX and analogues
• Wide range of therapeutic applications

 

BUSINESS OPPORTUNITY

• Technology available for in-licensing
• Seeking for industrial partner for co-development
• Eligibility to government financing for industry/academic maturation program

 

IP PROTECTION

• Active Patent: Can, US, EU (US9782379B2)
• Pending PCT
• Provisional Patent